Countouriotis Athena
- SEC CIK
- 0001571469
No open-market purchases or sales filed in the past year.
Current role at each company
- IOVA Iovance Biotherapeutics, Inc.Directoras of Jun 18, 2026
- BMRN Biomarin Pharmaceutical IncDirectoras of Jun 4, 2026
- PASG Passage BIO, Inc.Directoras of May 21, 2026
- TPTX Turning Point Therapeutics, Inc.President & CEOas of Aug 17, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Countouriotis Athena as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
TPTX Turning Point Therapeutics, Inc.
President & CEO1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 11, 2022 (view filing) | Feb 9 | 2 days | Countouriotis AthenaPresident & CEO | SSale | −2.97K | $36.30 | −$107.8K | −5.8%47.9K after |